In a drive to transform how medicines are discovered, developed, and used, Amgen and its deCODE Genetics subsidiary are mining human data at a scale that was once unimaginable. The latest feature story in Amgen Science takes an in-depth look at this important new element of Amgen’s R&D strategy. An excerpt:
The data points flowing from various branches of omics are like pixels that can be pieced together to build a sharper picture of how disease takes root and develops. The technology has the potential to deliver new biomarkers for earlier diagnosis of disease, faster and more successful clinical trials, and the ability to predict and prevent disease before it becomes more grievous and costly.
View the video above to hear more about the potential of omics to transform R&D, and read the full feature story at Amgen Science.